8-K: Tharimmune Stockholders Re-Elect Board, Ratify Auditor, and Approve Equity Plan at Annual Meeting

Tharimmune, Inc. announced the successful outcomes of its Annual Meeting of Stockholders held on June 10, 2025, where all director nominees were elected, the independent auditor was ratified, and the amended 2023 Omnibus Equity Incentive Plan was approved.

Summary

• Tharimmune, Inc. held its Annual Meeting of Stockholders on June 10, 2025, with a quorum of 1,129,458 shares of common stock represented.
• All seven nominated directors were elected to serve until the 2026 Annual Meeting of Stockholders.
• Randy Milby received 480,332 'For' votes, 296,465 'Abstain' votes, and 352,661 'Broker Non-Votes'.
• Kelly Anderson received 643,768 'For' votes, 133,028 'Abstain' votes, and 352,662 'Broker Non-Votes'.
• Sireesh Appajosyula, Sanam Parikh, Vincent LoPriore, Clay Kahler, and Gary Stetz each received over 760,000 'For' votes with significantly fewer 'Abstain' votes compared to Milby and Anderson.
• The appointment of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for fiscal year ended December 31, 2025, was ratified with 1,085,531 'For' votes, 40,995 'Against' votes, and 2,932 'Abstain' votes.
• The Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan was approved with 435,460 'For' votes, 339,548 'Against' votes, 1,789 'Abstain' votes, and 352,661 'Broker Non-Votes'.

Sentiment

Score: 6

Explanation: While all management proposals passed, the significant 'Against' votes for the equity incentive plan and higher 'Abstain' votes for two director nominees suggest some level of shareholder dissatisfaction or scrutiny, preventing a higher positive sentiment score.

Positives

• All seven director nominees were successfully elected to the board.
• The appointment of Rosenberg Rich Baker Berman P.A. as the independent auditor was overwhelmingly ratified by stockholders.
• The Amended and Restated 2023 Omnibus Equity Incentive Plan was approved, providing a framework for future equity compensation.

Negatives

• Randy Milby and Kelly Anderson received a notably higher number of 'Abstain' votes (296,465 and 133,028 respectively) for their re-election compared to other directors, indicating less shareholder consensus.
• The Amended and Restated 2023 Omnibus Equity Incentive Plan faced significant opposition, with 339,548 'Against' votes, representing a substantial portion of the votes cast (excluding broker non-votes).

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the election of directors to serve until the 2026 Annual Meeting.

Management Comments

• Randy Milby, Chief Executive Officer, signed the report on behalf of Tharimmune, Inc.

Industry Context

This 8-K filing details the routine outcomes of an annual stockholder meeting, which is a standard corporate governance event for publicly traded companies. The results reflect internal corporate decisions and shareholder sentiment rather than broader industry trends.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the election of directors who will oversee company strategy and governance, and by the approval of the equity incentive plan which could lead to share dilution.
• Employees: The approval of the equity incentive plan provides a framework for potential equity compensation, impacting employee incentives and retention.

Next Steps

• Elected directors will serve until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified.

Key Dates

Recommendation

Keywords

Tharimmune, THAR, Annual Meeting, Stockholders, Director Election, Corporate Governance, Auditor Ratification, Equity Incentive Plan, Proxy Statement, SEC Filing, 8-K